Link Details
- Metabolite
- HMDB0000067 (Cholesterol)
- DrugBank ID
- DB00625
- Drug Name
- Efavirenz
- Effect
- Increase
- Biospecimen
- Blood
- P-value
- Not Available
- Beta Estimator
- Not Available
- Percent Change
- Not Available
- Pearson Correlation Coefficient
- Not Available
- Comments
- Not Available
- Maggi P, Bellacosa C, Carito V, Perilli F, Lillo A, Volpe A, Trillo G, Angiletta D, Regina G, Angarano G: Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. J Antimicrob Chemother. 2011 Apr;66(4):896-900. doi: 10.1093/jac/dkq507. Epub 2011 Jan 20. [PubMed:21393134 ]
- Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Haas DW, Maartens G: Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations. Medicine (Baltimore). 2016 Jan;95(2):e2385. doi: 10.1097/MD.0000000000002385. [PubMed:26765416 ]
- Rao MN, Lee GA, Grunfeld C: Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. Am J Infect Dis. 2006 Sep 30;2(3):159-166. [PubMed:22162956 ]